The Mounjaro Dosing Schedule: What Each Step Is Actually For

Why the schedule starts so low, and why that's intentional

The first pen you inject contains 2.5 mg of tirzepatide. For many people that feels anticlimactic: the dose is small enough that appetite changes are subtle and weight loss in the first few weeks is often modest. That's by design. Mounjaro works through two gut-hormone receptors (GIP and GLP-1) and stimulating both at a higher dose from the outset produces significant nausea, vomiting and digestive disruption in most people. Starting low isn't cautious for caution's sake; it's the mechanism that makes the medicine tolerable long enough to actually work.

After four weeks at 2.5 mg, your prescriber will typically move you to 5 mg, which is where the therapeutic effect properly begins. The escalation then continues in 2.5 mg steps every four weeks: 7.5, 10, 12.5, and finally 15 mg. Each step up is a clinical decision. If side effects at a given dose are still unsettled, the prescriber may hold you there longer rather than push ahead. The details of each dose's role are worth understanding before you start, particularly if you're transferring from another treatment.

One thing the schedule can't tell you upfront: which dose will be your maintenance dose. Some people find substantial appetite reduction at 7.5 mg and stay there comfortably. Others need 15 mg to get the same effect. Biology varies, and the schedule exists to find your answer safely rather than assume it.

What actually determines when your dose increases

A common misconception is that the Mounjaro schedule is a conveyor belt, four weeks at each step, automatic increase, done. In practice, three things shape the pace: tolerability, clinical evidence of progress, and your prescriber's judgment on both.

Tolerability means whether the gastrointestinal side effects (nausea, loose stools, indigestion, reflux) have settled enough to handle a higher dose. These symptoms are most noticeable in the first week or two after an increase, then generally ease. If they haven't eased by week four, holding at the current dose for another month is the sensible call. Pushing up too quickly is the most common reason people abandon treatment early.

Clinical progress matters too. The licensed tirzepatide product information and NICE's appraisal (TA1026) both note that if someone hasn't lost at least 5% of body weight after six months at their highest tolerated dose, continuing the medicine is reviewed. That's not a threat; it's good clinical practice, the schedule is a tool for a goal, not a goal in itself.

Prescribers at regulated services review this before each repeat supply. At nume, no repeat is dispensed without a clinical reassessment. That's different from an automatic subscription refill, and it matters for safety.

The decision most people don't expect: staying put or stepping back

There are situations where the tirzepatide dosing schedule for weight loss moves in a direction other than up. If you have elective surgery coming up, your clinical team may advise pausing. If side effects are persistent at a given strength, dropping back to the previous dose temporarily is a legitimate and often sensible option. This isn't treatment failure, it's the schedule working as it's supposed to.

It's also worth knowing that dose increases are not guaranteed. A prescriber reviewing your progress may decide the current dose is working well enough that increasing it adds risk without proportionate benefit. The Mounjaro dose chart is a useful reference for visualising where you are and what comes next, but it's a map, not a mandate.

People sometimes ask about an unconventional approach, using smaller, more frequent doses rather than the standard weekly schedule. There is interest in what's sometimes called a microdose tirzepatide approach, though this sits outside the licensed schedule and requires specific prescriber oversight. It's not something to attempt independently.

The cost of treatment across the full titration period is a real consideration too, and the Eli Lilly UK price increase in 2025 changed what higher doses cost privately. It's worth being clear-eyed about that before you start.

What the schedule looks like at its end point, and what happens after

Most people who complete the full tirzepatide schedule reach 15 mg over roughly 20 weeks, though the real-world timeline is often longer when pauses and holds are factored in. The SURMOUNT-1 trial (2,539 adults, 72 weeks) reported average body-weight reductions of around 20–21% at the 15 mg dose, as published in the New England Journal of Medicine. Not everyone reaches 15 mg, and not everyone needs to; those results are at the ceiling dose in a controlled trial.

After reaching a maintenance dose, the schedule stabilises: one injection per week, same strength, ongoing clinical review. If treatment stops, weight typically returns over time, that's a biological fact about how GLP-1 and GIP receptor agonists work, not a flaw in the medicine. What happens when treatment ends is a conversation to have with your prescriber before you start, not after.

The NHS has its own framework for when tirzepatide is available publicly, but access is currently limited to specific clinical criteria under NICE's phased rollout. For people who don't meet those thresholds or can't wait, a private prescription through a regulated pharmacy is the alternative, provided the clinical assessment says it's appropriate. The full range of weight-loss treatments assessed at nume gives a clearer picture of what's available and how the process works. You can also read more about our approach to weight loss generally before deciding anything.

If you have specific questions about the dosing considerations for tirzepatide in your situation, a consultation with a prescriber is the right place to raise them, not a forum, and not the packaging alone. The NHS's patient information for tirzepatide, available on the NHS medicines page for tirzepatide, is a solid first read alongside whatever your prescriber tells you.